Attacking Cancers Using Novel Methods of Targeted Protein Degradation
SugarCone Biotech
OCTOBER 6, 2024
It is important to be clear that this is a unique degrader strategy and not at all like ProTAC or ProMAB technologies that targets proteins by binding them to the E3-ligase controlled degradation pathway. That is a complex field that has struggled to bring therapies to approval (see [link] ).
Let's personalize your content